Cabozantinib

Generic Name
Cabozantinib
Brand Names
Cabometyx, Cometriq
Drug Type
Small Molecule
Chemical Formula
C28H24FN3O5
CAS Number
849217-68-1
Unique Ingredient Identifier
1C39JW444G
Background

Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...

Indication

⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。

⑵用于舒尼替尼(索坦)治疗失败的晚期肾癌。

Associated Conditions
Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
Associated Therapies
-

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-06-25
Last Posted Date
2021-04-20
Lead Sponsor
Exelixis
Target Recruit Count
330
Registration Number
NCT00704730
Locations
🇺🇸

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Ohio State University, James Cancer Hospital, Columbus, Ohio, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 46 locations

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-06-24
Last Posted Date
2024-02-05
Lead Sponsor
Exelixis
Target Recruit Count
222
Registration Number
NCT00704288
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

and more 5 locations

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-01-17
Last Posted Date
2013-09-19
Lead Sponsor
Exelixis
Target Recruit Count
92
Registration Number
NCT00596648
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Georgetown University/Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

🇺🇸

Park Nicollet Institute, St. Louis Park, Minnesota, United States

and more 10 locations

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Phase 1
Completed
Conditions
Interventions
First Posted Date
2005-09-22
Last Posted Date
2013-02-27
Lead Sponsor
Exelixis
Target Recruit Count
85
Registration Number
NCT00215605
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath